{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-001061","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.029687+00:00","generated_at":"2026-06-07T00:47:44.397950+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TG Therapeutics licenses azer-cel, reports preliminary Q4 BRIUMVI revenue $40M, FY2024 guidance $220-260M","bullets":["Upfront payment to Precision: $7.5M ($5.25M cash + $2.25M equity); deferred $2.5M equity; up to $288M milestone payments plus high-single-digit to low-double-digit royalties.","Preliminary Q4 2023 BRIUMVI U.S. net product revenue ~$40M, full year ~$89M; year-end cash ~$215M.","2024 guidance: BRIUMVI U.S. net product revenue target $220-260M, Q1 target $41-46M; operating expense ~$250M.","2024 pipeline milestones: start trials for subcutaneous BRIUMVI, BRIUMVI in other autoimmune diseases, and azer-cel in autoimmune disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-001061","json":"https://secwatch.observer/filing/0001437749-24-001061.json","markdown":"https://secwatch.observer/filing/0001437749-24-001061.md","text":"https://secwatch.observer/filing/0001437749-24-001061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774924001061/0001437749-24-001061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774924001061/tgtx20240109_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:47:44.397950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"819cbdb51dae34439e6c2e5dfa2695be332764dd","claim":"TG THERAPEUTICS, INC. entered into License Agreement with Precision BioSciences, Inc. valued at $7.5 million (effective 2024-01-07).","evidence_excerpt":"On January 7, 2024, TG Therapeutics, Inc. (the “Company”) and its wholly-owned subsidiary, TG Cell Therapy, Inc., entered into a License Agreement (the “License Agreement”) with Precision BioSciences, Inc. (“Precision”), pursuant to which Precision granted the Company certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize Precision’s allogeneic CAR T therapy azercabtagene zapreleucel (“azer-cel”) for the treatment of autoimmune and other non-oncology diseases and conditions (collectively, the “Field”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001316/000143774924001061/0001437749-24-001061-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Precision BioSciences, Inc."},{"label":"Value","value":"$7.5 million"},{"label":"Effective","value":"2024-01-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}